[This review was originally posted at the Nieman Journalism Lab Purchase Synthroid, on August 24, 2012.]
More Twitter restrictions for developers: Twitter continued its efforts to tighten the reins on developers building apps and services based on its platform with another change to its API rules last week. Most of it is pretty incomprehensible to non-developers, but Twitter did make itself plain at one point, saying it wants to limit development by engagement-based apps that market to consumers, rather than businesses. (Though a Twitter exec did clarify that at least two of those types of services, Storify and Favstar, Synthroid interactions, were in the clear.)
The Next Web's Matthew Panzarino clarified some of the technical jargon, and Marketing Land's Danny Sullivan explained whom this announcement means Twitter likes and doesn't like, and why. ReadWriteWeb's Dan Frommer gave the big-picture reason for Twitter's increasing coldness toward developers — it needs to generate tons more advertising soon if it wants to stay independent, and the way to do that is to keep people on Twitter, rather than on Twitter-like apps and services. (Tech entrepreneur Nova Spivack said that rationale doesn't fly, and came up with a few more open alternatives to allow Twitter to make significant money.)
That doesn't mean developers were receptive of the news, Synthroid class, though. Panzarino said these changes effectively kill the growth of third-party products built on Twitter's platform, and Instapaper founder Marco Arment argued that Twitter has made itself even harder to work with than the famously draconian Apple. Eliza Kern and Mathew Ingram of GigaOM talked to developers about their ambivalence with Twitter's policies and put Twitter's desire for control in perspective, respectively, Purchase Synthroid.
Several observers saw these changes as a marker of Twitter's shift from user-oriented service to cog in the big-media machine. Tech designer Stowe Boyd argued Twitter "is headed right into the central DNA of medialand," and tech blogger Ben Brooks said Twitter is now preoccupied with securing big-media partnerships: "Twitter has sold out. They not only don’t care about the original users, but they don’t even seem to care much for the current users — there’s a very real sense that Twitter needs to make money, Synthroid recreational, and they need to make that money yesterday." Developer Rafe Colburn pointed out how many of Twitter's functions were developed by its users, and developer Nick Bruun said many of the apps that Twitter is going after don't mimic its user experience, but significantly improve it. Killing those apps and streamlining the experience, said GigaOM's Mathew Ingram, doesn't help users, but hurts them. Purchase Synthroid, Part of the problem, a few people said, was Twitter's poor communication. Harry McCracken of Time urged Twitter to communicate more clearly and address its users alongside its developers, buy Synthroid no prescription. Tech entrepreneur Anil Dash offered a rewritten (and quite sympathetic) version of Twitter's guidelines.
There's another group of developers affected by this change — news developers. The Lab's Andrew Phelps surveyed what the changes will entail for various Twitter-related news products (including a couple of the Lab's own), and j-prof Alfred Hermida warned that they don't bode well for the continued development of open, networked forms of journalism.
Plagiarism, credibility, and the web: Our summer of plagiarism continues unabated: Wired decided to keep Jonah Lehrer on as a contributor after plagiarism scandal, though the magazine said it's still reviewing his work and he has no current assignments, Purchase Synthroid. Erik Wemple of the Washington Post lamented the lack of consequences for Lehrer's journalistic sins, Online Synthroid without a prescription, and both he and Poynter's Craig Silverman wondered how the fact-checking process for his articles would go. Meanwhile, Lehrer was accused by another source of fabricating quotes and also came under scrutiny for mischaracterizing scientific findings.
The other plagiarizer du jour, Time and CNN's Fareed Zakaria, has come out much better than Lehrer so far. Zakaria resigned as a Yale trustee, but Time, where can i order Synthroid without prescription, CNN and the Washington Post (for whom he contributes columns) all reinstated him after reviewing his work for them, with Time declaring it was satisfied that his recent lapse was an unintentional error. Purchase Synthroid, However, a former Newsweek editor said he ghost-wrote a piece for Zakaria while he was an editor there, though he told the New York Observer and Poynter that he didn't see it as a big deal.
Some defended Zakaria on a variety of grounds. Poynter's Andrew Beaujon evaluated a few of the arguments and found only one might have merit — that the plagiarism might have resulted from a research error by one of his assistants. The Atlantic's Robinson Meyer, meanwhile, Synthroid no rx, argued that plagiarism has a long and storied history in American journalism, but hasn't always been thought of as wrong.
Others saw the responses by news organizations toward both Zakaria and Lehrer as insufficient. Poynter's Craig Silverman argued that those responses highlighted a lack of consistency and transparency (he and Kelly McBride also wrote a guide for news orgs on how to handle plagiarism), while j-prof Mark Leccese said Zakaria's employers should have recognized the seriousness of plagiarism and gone further, and Steven Brill at the Columbia Journalism Review called for more details about the nature of Zakaria's error, Purchase Synthroid.
A New York Times account of Zakaria's error focused on his hectic lifestyle, filled with the demands of being a 21st-century, multiplatform, personally branded pundit. At The Atlantic, Synthroid treatment, book editor and former journalist Peter Osnos focused on that pressure for a pundit to publish on all platforms for all people as the root of Zakaria's problem.
The Times' David Carr pinpointed another factor — the availability of shortcuts to credibility on the web that allowed Lehrer to become a superstar before he learned the craft. (Carr found Lehrer's problems far more concerning than Zakaria's.) At Salon, Michael Barthel also highlighted the difference between traditional media and web culture, arguing that the problem for people like Zakaria is their desire to inhabit both worlds at once: "The way journalists demonstrate credibility on the Web isn’t better than how they do in legacy media. It’s just almost entirely different Purchase Synthroid, . For those journalists and institutions caught in the middle, that’s a real problem." GigaOM's Mathew Ingram argued that linking is a big part of the web's natural defenses against plagiarism.
Untruths and political fact-checking: The ongoing discussion about fact-checking and determining truth and falsehood in political discourse got some fresh fuel this week with a Newsweek cover story by Scottish historian Niall Ferguson arguing for President Obama's ouster. Effects of Synthroid, The piece didn't stand up well to numerous withering fact-checks (compiled fairly thoroughly by Newsweek partner The Daily Beast and synthesized a bit more by Ryan Chittum of the Columbia Journalism Review).
Ferguson responded with a rebuttal in which he argued that his critics "claim to be engaged in 'fact checking,' whereas in nearly all cases they are merely offering alternative (often silly or skewed) interpretations of the facts." Newsweek's editor, Tina Brown, likewise referred to the story as opinion (though not one she necessarily agreed with) and said there isn't "a clear delineation of right and wrong here."
Aside from framing the criticism as a simple difference of opinion rather than an issue of factual (in)correctness, Newsweek also acknowledged to Politico that it doesn't have fact-checkers — that its editors "rely on our writers to submit factually accurate material." Poynter's Craig Silverman provided some of the history behind that decision, which prompted some rage from Charles Apple of the American Copy Editors Society. Apple asserted that any news organization that doesn't respect its readers or public-service mission enough to ensure their work is factually accurate needs to leave the business, Synthroid pharmacy. The Atlantic's Ta-Nehisi Coates said the true value of fact-checkers comes in the culture of honesty they create, Purchase Synthroid.
Mathew Ingram of GigaOM wondered if that fact-checking process might be better done in public, where readers can see the arguments and inform themselves. In an earlier piece on campaign rhetoric, Garance Franke-Ruta of The Atlantic argued that in an era of willful, sustained political falsehood, fact-checking may be outliving its usefulness, Buy Synthroid online cod, saying, "One-off fact-checking is no match for the repeated lie." The Lab's Andrew Phelps, meanwhile, went deep inside the web's leading fact-checking operation, PolitiFact.
The Times' new CEO and incremental change: The New York Times Co. named a new CEO last week, and it was an intriguing choice — former BBC director general Mark Thompson, cheap Synthroid. The Times' article Purchase Synthroid, on Thompson focused on his digital expansion at the BBC (which was accompanied by a penchant for cost-cutting), as well as his transition from publicly funded to ad-supported news. According to the International Business Times, those issues were all sources of skepticism within the Times newsroom. Bloomberg noted that Thompson will still be subject to Arthur Sulzberger's vision for the Times, and at the Guardian, Michael Wolff said Thompson should complement that vision well, as a more realistic and business-savvy counter to Sulzberger. Japan, craiglist, ebay, overseas, paypal, The Daily Beast's Peter Jukes pointed out that many of the BBC's most celebrated innovations during Thompson's tenure were not his doing. Robert Andrews of paidContent also noted this, but said Thompson's skill lay in being able to channel that bottom-up innovation to fit the BBC's goals. Media analyst Ken Doctor argued that the BBC and the Times may be more alike than people think, and Thompson's experience at the former may transfer over well to the latter: "Thompson brings the experience at moving, too slowly for some, too dramatically for others, a huge entity." But Mathew Ingram of GigaOM said that kind of approach won't be enough: "The bottom line is that a business-as-usual or custodial approach is not going to cut it at the NYT, not when revenues are declining as rapidly as they have been."
Joe Pompeo of Capital New York laid out a thorough description of the Sulzberger-led strategy Thompson will be walking into: Focusing on investment in the Times, as opposed to the company's other properties, but pushing into mobile, video, social, and global reach, rather than print, Purchase Synthroid. And Bloomberg's Edmund Lee posited the idea that the Times could be in increasingly good position to go private.
The Assange case and free speech vs. women's rights: WikiLeaks' Julian Assange cleared another hurdle last week — for now — in his fight to avoid extradition to Sweden on sexual assault accusations when Ecuador announced it would grant him asylum. Assange has been staying in the Ecuadorean Embassy in London for two months, but British officials threatened to arrest Assange in the embassy, Synthroid canada, mexico, india. Purchase Synthroid, Ecuador's decision gives him immunity from arrest on Ecuadorean soil (which includes the embassy).
Assange gave a typically defiant speech for the occasion, but the British government was undeterred, saying it plans to resolve the situation diplomatically and send Assange to Sweden. Ecuador's president said an embassy raid would be diplomatic suicide for the U.K., and Techdirt's Mike Masnick was appalled that Britain would even suggest it. Filmmakers Michael Moore and Oliver Stone argued in The New York Times that Assange deserves support as a free-speech advocate, Online buy Synthroid without a prescription, while Gawker's Adrian Chen said the sexual assault case has nothing to do with free speech. Laurie Penny of The Independent looked at the way free speech and women's rights are being pitted against each other in this case.
Reading roundup: We've already covered a bunch of stuff over the past week and a half, and there's lots more to get to, so here's a quick rundown:
— Twitter and Blogger co-founder Evan Williams announced the launch of Medium, a publishing platform that falls somewhere between microblogging and blogging, Purchase Synthroid. The Lab's Joshua Benton has the definitive post on what Medium might be, Dave Winer outlined his hopes for it, and The Awl's Choire Sicha wrote about the anti-advertising bent at sites like it.
— A few social-news notes: Two features from the Huffington Post and The Lab on Buzzfeed's ramped-up political news plans; TechCrunch's comparison of Buzzfeed, Reddit, and Digg; and a feature from the Daily Dot on Reddit and the future of social journalism.
— The alt-weekly The Village Voice laid off staffers late last week, prompting Jim Romenesko to report that the paper is on the verge of collapse and Buzzfeed's Rosie Gray to chronicle its demise. Poynter's Andrew Beaujon said the paper still has plenty left, and The New York Times' David Carr said the problem is that the information ecosystem has outgrown alt-weeklies.
— Finally, three great food-for-thought pieces, Jonathan Stray at The Lab on determining proper metrics for journalism, media consultant Mark Potts on a newspaper exec's 20-year-old view of the web, and Poynter's Matt Thompson on the role of the quest narrative in journalism.
Similar posts: Bactrim Price. Synthroid Price. Order Tramadol. Retin A from mexico. Armour no prescription. Lipitor maximum dosage.
Trackbacks from: Purchase Synthroid. Purchase Synthroid. Purchase Synthroid. Purchase Synthroid online. Synthroid alternatives. Synthroid blogs.
[This review was originally posted at the Nieman Journalism Lab Purchase Lipitor, on March 18, 2011.]
First reactions to The Times' paid-content plans: Yesterday The New York Times rolled out the online paid-content plans they've been talking about for a little more than a year. You get 20 articles a month for free (besides the ones you get to through Google and social media), and after that it's going to cost you anywhere from $15 to $35 per four weeks, depending on what devices you want to access it on. Print subscribers will get it all for free. (Yup, as the Lab's Josh Benton and Forbes' Jeff Bercovici pointed out, that means there are print plans with online access that are cheaper than the online-only ones.) Subscriptions will sold, Lipitor results, among other places, in Apple's iTunes store. Here's The Times' letter to readers and news article, as well as the Lab's glimpse at the paywall and a good paidContent FAQ.
Now for the reaction and analysis: If you only have time for a few pieces, make them Ken Doctor, Steve Outing, and Felix Salmon, Purchase Lipitor. If you want a quick sampler platter of opinions, you can't do any better than the Lab's roundup of 11 experts' thoughts.
There was no consensus of initial opinion about the plan; many supporters spoke up quickly, including The Times' own media critic, David Carr, purchase Lipitor, and The Daily Beast's Howard Kurtz. Poynter newspaper analyst Rick Edmonds broke down the ways it met all the initial criteria of a sound paywall plan, and British j-prof Paul Bradshaw called it "the most mature, intelligent, and commercially sensible paywall model yet," praising its respect for distribution and online engagement. At The Columbia Journalism Review, Lipitor over the counter, Ryan Chittum said it looked good, and Lauren Kirchner issued a rejoinder to the "information wants to be free" crowd. Purchase Lipitor, The Times' detractors were quick to speak up, too. Media analyst Steve Outing laid out most of the basic objections: The prices are too high, people will turn away when they hit the 20-article limit, and the differentiation by device doesn't make sense. (TechCrunch's Erick Schonfeld harped on the latter point, too.) Reuters' Felix Salmon chimed in by saying that the price point is high enough that a lot of regular readers won't subscribe (meaning the plan won't bring in much revenue anyway), and that the Times is discouraging use of its iPad.
At BoingBoing, Lipitor forum, Cory Doctorow said most users will find the metering system frustrating, leading them to find other ways to read The Times or just not read it at all. Techdirt's Mike Masnick made a similar point, adding that The Times isn't adding any value with the plan. That was tech pioneer Dave Winer's main beef: "They're not offering anything to readers other than the Times' survival, and they're not even explicit about that."
Plenty of commentary didn't fall into either the "pro" or "con" camp, of course, Purchase Lipitor. Here at the Lab, Ken Doctor provided the definitive economic analysis of the plan, breaking down the seven tests it must pass to be successful. Discount Lipitor, Then there was the issue of getting around the paywall (or, as Doctor more accurately called it, the fence): Business Insider told us how to do it via Google, and TechCrunch pontificated on the social media loophole that will develop in addition to the current Google one. Media consultant Steve Yelvington downplayed that factor: "It's not supposed to be a bank vault, people. It's a polite request for payment."
Another obvious next question is whether this could be applied to other news organizations. Purchase Lipitor, Meranda Watling of 10,000 Words compared the plan with those of The Wall Street Journal and Newsday, but Amy Gahran of the Knight Digital Media Center gave other newspapers a stern "don't try this at home."
Breaking down an old debate at SXSW: Just as they do every March, geeks descended on Austin, Texas, last weekend for the South by Southwest Interactive Festival, and as usual, there was plenty of journalism-related stuff to chew on, even for those of us who didn't attend. The session that seemed to get the most traction online was NYU professor Jay Rosen's psychological analysis of the tension between bloggers and journalists — which is perhaps a bit surprising for a battle that Rosen himself declared "over" six years ago.
Rosen's whole talk is worth a read, online buy Lipitor without a prescription, but here's the gist of it: For journalists, bloggers are the idealized face of all the ideological and professional stresses they deal with, and for bloggers, the conflict helps keep them on the "outside" of the system, allowing them to maintain their innocence and rhetorical power. Snarkmarket's Matt Thompson and Tim Carmody liveblogged their analysis of the talk, and The Guardian summarized it. Lipitor pics, Michele McLellan of the Knight Digital Media Center ripped blogger-hating journalists for fighting an outdated war, but Melissa Bell of the Washington Post called Rosen's characterization of objectivity misleading.
There were plenty of other panels worth reading about, too, including NYU prof Clay Shirky's timely talk on social media and revolution, in which he said that governments routinely overestimate our access to information and underestimate our access to each other, Purchase Lipitor. (The Guardian had a short summary, and Poynter's Julie Moos put together a blow-by-blow in Storify.)
There were also a couple of panels on the value of gaming, particularly in news, as well as sessions on building trust online, using social media to evade censorship, the future of public media, iPad news apps, is Lipitor safe, and SEO tips from Google and Bing. Poynter's Steve Myers pulled together a dozen journalists for an overview of the conference in terms of building community, and an Economist blogger tied this year's SXSW to last year's with a sharp post questioning the story as the basic unit of journalism.
A critical eye on NPR's antagonists: The damage to NPR from James O'Keefe's hidden-camera exposé was already done last week, but the scrutiny of the tape itself didn't begin in earnest until the weekend — kicked off by, of all places, Glenn Beck's website, Lipitor from canada, The Blaze. (Time's James Poniewozik's breakdown is also worth a read.) The site's skepticism of the video's editing was picked up by NPR media reporter David Folkenflik, who examined the issue in a broadcast report. NPR's spokeswoman called the video Purchase Lipitor, "inappropriately edited," but said the executive in the tape had still made "egregious statements."
Whatever O'Keefe's ethics, Poynter's Steve Myers said, there's plenty he understands about today's media environment that we can learn from: Investigative journalism is in demand, raw media communicates "reality," and soundbites and reducing opponents' logic to absurdities trump context in the online media world.
The change in leadership at NPR prompted others to look at the health and direction of the organization overall: The New York Times' David Carr examined NPR's success in light of the public-funding argument, and Poynter's Mallary Jean Tenore laid out the four biggest challenges for NPR's next CEO. The Lab's Nikki Usher looked overseas for public media comparisons, and The Columbia Journalism Review talked to Jonathan Holmes of the Australian Broadcasting Corporation about the public media situation there.
A snapshot of the state of journalism: Pew's Project for Excellence in Journalism released its annual State of the Media report this week, summarizing last year as a good one for journalism. The big headline that most media outlets took away from the study was that for the first time, online news consumption has surpassed newspaper use. There were plenty of other nuggets from the study, though, covering a variety of news media.
The study outlined the state of the newspaper industry, touching on all the major themes from circulation to advertising to digital paid-content efforts, Purchase Lipitor. One of the authors of that part of the study, Poynter's Rick Edmonds, Lipitor overnight, summarized the trends he found interesting.
It also included a look at the economics of startup community journalism, with discussion of nonprofits, ad-based sites, and the Patch model. (Author Michele McLellan summarized her main points here.) The researchers also reported on a survey on mobile news use, and Amy Gahran of the Knight Digital Media Center and Damon Kiesow of Poynter highlighted some of the opportunities for news organizations in its results.
A couple of other tidbits from the study: Search Engine Land's Vanessa Fox focused on revenue from advertising, subscriptions, Lipitor alternatives, and mobile apps, and j-prof Alfred Hermida pointed out the difference between the news agendas of Twitter, blogs and the mainstream media.
Twitter tells developers to hold off: Twitter made waves in the tech world late last week when they posted a note Purchase Lipitor, telling developers not to develop any more Twitter clients, saying they'd like to do it themselves, ostensibly for consistency's sake. (Mashable has a great explanation of the issue.) Most of the initial reaction was not enthusiastic: Salon's Dan Gillmor said the note was a reminder that we need other options for our online platforms that aren't controlled by a single company, and Dave Winer said it reinforces the fact the open web is the best place to develop.
Mathew Ingram of GigaOM and developer Fred Oliveira both urged Twitter to rethink its decision, noting that third-party apps like Tweetdeck and Tweetie spurred much of Twitter's initial growth. Lipitor without prescription, And ReadWriteWeb's Marshall Kirkpatrick saw this as a hint at where Twitter is headed culturally: "If you thought Twitter was a place for outlaws, for free thinkers, for innovators - you need to tuck in your shirt, cut your hair and get a clue."
Others, however, defended Twitter: Social media marketer Jesse Stay said he wishes Twitter had done this a while ago, and developer Rob Diana argued that Twitter has finally given developers a solid sense of direction while still giving them some freedom.
Reading roundup: A few notes to digest while your bracket goes up in flames:
— The big news story of the past week has been the earthquake, tsunami and their aftermath in Japan, Lipitor online cod. There wasn't a whole lot written about it from a media perspective, but there were a couple of insightful posts, Purchase Lipitor. Doc Searls looked at coverage and concluded that the web is subsuming TV and radio, and Jeff Jarvis asked for separate Twitter hashtags for breaking news event witnesses.
— A few leftover AOL/Huffington Post items: GigaOM's Mathew Ingram looked at why AOL is desperate for some successful content initiatives, Arianna Huffington talked SEO, TechCrunch broke down the journalism/churnalism tension at AOL, and The New York Times' Bill Keller issued a non-apology followup to his Huffington-bashing essay last week.
— A couple of stray items from the commenting discussion of the last couple of weeks: Via O'Reilly Radar, Effects of Lipitor, statistics showing the integration of Facebook Comments led to fewer comments at TechCrunch, and a defense of anonymous commenting from Paul O'Flaherty.
— Finally, the Lab has the transcript of an interesting talk Northwestern prof Pablo Boczkowski gave about the gap between what news consumers want and what they get, with a thoughtful response from the Lab's Josh Benton. Enjoy.
Similar posts: Diflucan Cost. Diflucan For Sale. Armour Price. Cipro alternatives. Armour blogs. Diflucan duration.
Trackbacks from: Purchase Lipitor. Purchase Lipitor. Purchase Lipitor. Lipitor results. Lipitor street price. Generic Lipitor.